MESOTHELIOMA VS PLEURAL METASTASIS RADIOLOGY - MESOTHELIOMA AND MALIGNANT PLEURAL ISSUES

MESOTHELIOMA VS PLEURAL METASTASIS RADIOLOGY
➡️ http://MesotheliomaUSA.net




1. Background.

Malignant pleural mesothelioma (MPM) is a rare malignant neoplasm that typically affects individuals occupationally exposed to asbestos through a variety of industries. MPM is cancerous proliferation of mesothelial cells that involves a large extent of the pleural cavity and is the most common primary neoplasm of the pleura. The patients experience an insidious onset of symptoms including dyspnea, chest pain, cough, malaise, and weight loss.

Metastatic pleural tumor is a type of cancer that has spread from another organ to the membrane (pleura) surrounding the lungs. Lung and breast cancers most commonly spread to the lung. However, almost any type of cancer can spread to the lungs. The pathological diagnosis of MPM is difficult and special stains or immunohistological or ultra-structural analysis may be required to differentiate MPM from metastatic carcinoma of the pleura. Imaging plays an essential role in the evaluation of MPM. The radiographic findings of mesothelioma are nonspecific and more common diseases such as benign asbestos related pleural disease and metastatic carcinoma can look radiographically identical to mesothelioma. Computed tomography is the primary imaging modality used for diagnosis and staging of MPM. Generally, the combination of accurate history, examination, radiology, and the acquisition of pathology is essential to diagnose mesothelioma.

2. Objectives.

The aim of this study is to differentiate MPM from metastatic carcinoma of the pleura by pathological and radiological assessment in order to investigate ability and accuracy of CT scan in this regard and also to evaluate CT features of these two diseases.

3. Patients and Methods.

We conducted a retrospective study of 55 pleural malignancy patients including MPM and metastatic pleural disease cases hospitalized from 2009 through 2012 at a chronic respiratory center in Iran. Pathology and immunohistochemistry reports were considered as gold standard. The IHC panel of antibodies for differentiating malignant mesothelioma and metastatic carcinoma were HBME7, WT9, 0240, calretinin, CEA, MOC31, and CK5/6. Chest CT scans were performed in all patients with and without contrast with a single detector row CT scanner (Somatom plus; Siemens, Germany).

CT scans were observed by a chest radiologist, unaware of pathologic diagnosis. A checklist of relevant findings was fulfilled for each case and the most probable diagnosis according to CT scan was made by the radiologist.

Studied CT features consisted of pleural and pericardial effusion, pleural and pericardial thickening, parenchymal infiltration, fibrotic band, subpleural nodule, contralateral extension, contraction of involved hemithorax, pleural mediastinal shift, lymphadenopathy, thickening of the interlobar fissure, diaphragmatic involvement, and chest wall/hepatic/intraperitoneal invasion.

Data analysis was carried out using SPSS ver. 16 (SPSS for Windows, SPSS Inc., Chicago, IL) and the accuracy of radiology for differentiating MPM and metastatic carcinoma of the pleura was evaluated. Continuous variables were described by mean and standard deviation (SD) and categorical variables were described by frequency and percentage. CT findings were classified according to their prevalence and their contributing role for differentiating between mesothelioma and metastatic carcinoma.

MESOTHELIOMA VS PLEURAL METASTASIS RADIOLOGY - MESOTHELIOMA AND MALIGNANT PLEURAL ISSUES
https://www.youtube.com/watch?v=-IJNCRvW5HE
https://www.youtube.com/channe....l/UCqL1ImVqMKM51W4WC

#mesotheliomaandmalignantpleuralissues #whatyouneedtoknowaboutmesothelioma #casepresentationmesothelioma

🔗 https://www.ncbi.nlm.nih.gov/p....mc/articles/PMC48372

• Category

  Mesothelioma